Search for dialysis centres here

Find a centre Log in to explore the world's most comprehensive database of dialysis centres for free!

Jobs in dialysis

dialysis.team.logo.small.000 Professional dialysis recruitment 

 

New Oral Kinase Inhibitor Axitinib Approved for Advanced Renal Cancer - Pharmacy Practice News PDF Print

New Oral Kinase Inhibitor Axitinib Approved for Advanced Renal Cancer
Pharmacy Practice News
The FDA has approved the oral kinase inhibitor axitinib (Inlyta, Pfizer) for treatment of patients with advanced renal cell carcinoma after failure of one prior systemic therapy, according to press releases from the FDA and Pfizer.
FDA clears drug for advanced kidney cancer The Korea Herald
FDA Grants Approval to Axitinib for the Treatment of Advanced Renal Cell Carcinoma Cancer Network
FDA OKs Pfizer's Inlyta and accepts NDA for bosutinib The Pharma Letter
TopNews New Zealand  - MedReps (subscription)  - Genetic Engineering News
all 7 news articles »

...
 
Share |

Dialysis travel

Dialysis information

Global Dialysis

Copyright © 2025 Global Dialysis. All Rights Reserved.